{"resourceType": "ArtifactAssessment", "id": "179693", "meta": {"versionId": "8", "lastUpdated": "2025-07-13T13:51:40.308Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/certainty-of-evidence"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-description", "valueMarkdown": "This example of a CertaintyOfEvidence Profile shows a recursive pattern of component elements with type/classifier paired values for different aspects of rating the certainty of evidence."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/179693", "assigner": {"display": "Computable Publishing LLC"}}], "title": "Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)", "artifactReference": {"reference": "Evidence/55", "type": "Evidence", "display": "14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)"}, "content": [{"summary": "GRADE rating system", "type": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "rating-system", "display": "Rating System"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/uv/ebm/CodeSystem/evidence-rating-system-classifier-codesystem", "code": "GRADE", "display": "GRADE"}]}]}, {"summary": "Low certainty due to inconsistency and risk of bias", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Overall", "display": "Overall certainty"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "low", "display": "Low quality"}]}], "component": [{"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "PublicationBias", "display": "Publication bias"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}]}, {"summary": "There is a high degree of heterogeneity (I-squared = 73%). There is also inconsistency in findings between the fixed-effect and random-effects statistical models.", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Inconsistency", "display": "Inconsistency"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "serious-concern", "display": "serious concern"}]}]}, {"summary": "Although the random-effects analysis finds an estimate without statistical significance, this imprecision is explained by the inconsistency (heterogeneity) and thus not further downrated in certainty assessment.", "type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Imprecision", "display": "Imprecision"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "Indirectness", "display": "Indirectness"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "no-concern", "display": "no serious concern"}]}]}, {"type": {"coding": [{"system": "http://hl7.org/fhir/certainty-type", "code": "RiskOfBias", "display": "Risk of bias"}]}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "serious-concern", "display": "serious concern"}]}], "component": [{"summary": "No blinding (no placebo control) in the largest trial", "type": {"coding": [{"system": "https://fevir.net/sevco", "code": "SEVCO:00035", "display": "Inadequate blinding of participants"}], "text": "Lack of blinding"}, "classifier": [{"coding": [{"system": "http://hl7.org/fhir/certainty-rating", "code": "present", "display": "present"}]}]}]}]}], "citeAs": "Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) [Database Entry: FHIR ArtifactAssessment Resource]. Contributors: In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179693. Revised 2025-07-13. Available at: https://fevir.net/resources/ArtifactAssessment/179693. Computable resource at: https://fevir.net/resources/ArtifactAssessment/179693#json."}